

Migraine Attack Treatment Response Molecular and Clinical Biomarkers (MAMBO) Phase I

NCT06503848

Status	RECRUITING
Sponsor	Hospital Universitari Vall d'Hebron Research Institute
Enrollment	108 participants

Key Eligibility Criteria

Inclusion (5)

- Migraine with or without aura diagnosis according to ICHD-3 criteria
- <8 migraine days per month
- Be able to read, write and understand instructions.
- Have internet access and mail address
- Signing of the informed consent

Exclusion (7)

- Active preventive treatment for migraine
- Active medication with an effect over the central nervous system
- Serious physical or psychiatric condition
- Cardiovascular or hepatic disease
- Pregnant or breastfeeding women
- ... and 2 more (see full listing online)

Locations (1 total)

Hospital Universitari Vall d'Hebron, Barcelona, Spain